---
title: "Exelixis NDA review for zanzalintinib plus atezolizumab extended; PDUFA date moved to Mar 3, 2027"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298721674.md"
description: "Exelixis announced that the FDA has extended the review period for its New Drug Application (NDA) for zanzalintinib plus atezolizumab by three months. Consequently, the Prescription Drug User Fee Act (PDUFA) date has been moved to March 3, 2027. This extension follows Exelixis' submission of updated safety and efficacy data in response to an FDA information request, which was deemed a major amendment."
datetime: "2026-09-11T11:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298721674.md)
  - [en](https://longbridge.com/en/news/298721674.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298721674.md)
generator: "portal-rs"
---

# Exelixis NDA review for zanzalintinib plus atezolizumab extended; PDUFA date moved to Mar 3, 2027

**Exelixis announced the FDA extended the NDA review for zanzalintinib with atezolizumab by three months, setting a new PDUFA date of March 3, 2027.**

**Key Highlights:**

-   FDA extended review of Exelixis' NDA for zanzalintinib plus atezolizumab by three months.
-   Extension follows Exelixis' submission of updated safety and efficacy data in response to an FDA information request.
-   FDA deemed the submission a major amendment, moving the PDUFA action date to March 3, 2027.

Original SEC Filing: EXELIXIS, INC. \[ EXEL \] - 8-K - Sep. 11, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [EXEL.US](https://longbridge.com/en/quote/EXEL.US.md)

## Related News & Research

- [How Investors May Respond To Exelixis (EXEL) Strong Earnings And Buyback](https://longbridge.com/en/news/304745460.md)
- [Exelixis Plans Fireside Chats at Four Investor Conferences](https://longbridge.com/en/news/304165438.md)
- [The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation](https://longbridge.com/en/news/304777376.md)
- [Exelixis Q3 2026 net income rises 13% to $218.1 million](https://longbridge.com/en/news/303623175.md)
- [How Investors May Respond To Alibaba (BABA) Dakar Olympics Cloud Deal](https://longbridge.com/en/news/305185166.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**